Both indications for the CTLA-4 inhibitor were approved by the FDA in 2022.
Samantha Brongiel, PharmD, BCOP
Advertisement
Articles by Samantha Brongiel, PharmD, BCOP
The agent is representative of a new class of drug, ImmTAC.
Advertisement
Latest Updated Articles
Addition of Tremelimumab-actl to Durvalumab-Based Regimen May Broaden Clinical Activity in uHCC, mNSCLCPublished: February 15th 2023 | Updated:
Tebentafusp-tebn Use in HLA-A*02:01–Positive Unresectable or Metastatic Uveal MelanomaPublished: October 18th 2022 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
2
Regular Melatonin Supplementation May Hide Hidden Heart Complications
3
Early Detection of Type 1 Diabetes: The Power of Screening and Preparation
4
COVID-19 During Pregnancy Raises Neurodevelopmental Risks in Children
5
